Advertisement

Participation in Clinical Trials as a Clinical Trialist for the Community Surgeon

  • Jonah D. Klein
  • Ned Z. CarpEmail author
Chapter
Part of the Success in Academic Surgery book series (SIAS)

Abstract

The definition of a community hospital has been highly variable based on teaching versus non-teaching, proximity to a major metropolitan area, number of hospital beds, governance structure, partnered or not partnered with a larger center, or simply its role as a care hub for the local population. For the purpose of this chapter, the term community hospital will refer to the American Hospital Associations definition as a non-federal, short-term, general, and/or specialty hospitals. This excludes university centers, but includes university affiliates and can be teaching or non-teaching. In 1980, 16% of outpatient surgeries took place at community hospitals. In 2015, this number increased to 66% (National Center for Health Statistics, Center for Disease Control, 2017). Similar trends are being seen in cancer care. Since clinical trials (inclusive of pharmaceutical trials, device trials, quality of life trials, and others) are the means by which the medical and surgical community evaluate and improve care for patients, it is imperative that the population of patients who receive their care at community centers have the opportunity to enroll in clinical trials. Similarly, surgeons in these settings must be armed with the tools needed to participate in clinical trials. This chapter outlines the community surgeon’s involvement in clinical trials. Discussed are the historic perspective (including community participation in practice changing trials), the logistic challenges and barriers in the community hospital, and the unique elements of trials in the community setting compared to the university-based academic settings.

Keywords

Community Surgeon NCORP Barriers Trials Personnel 

Notes

Acknowledgements

Paul B. Gilman, M.D., Albert DeNittis, M.D., M.S., Jarrod Kauffman, M.D., Alexander Uribe, M.D., John Wellenbach, John H. Marks, M.D.

References

  1. 1.
    National Center for Health Statistics, Center for Disease Control. 2017. https://www.cdc.gov/nchs/hus/contents2017.htm?search=Hospital_use. Accessed 26 Mar 2019.
  2. 2.
    Bauer TL Sr, Boughey JC. Community-based physicians and hospitals need to participate in clinical trials. Bull Am Coll Surg. 2014;99(4):46–7.PubMedGoogle Scholar
  3. 3.
    Begg CB, Carbone PP, Elson PJ, Zelen M. Participation of community hospitals in clinical trials—analysis of five years of experience in the eastern cooperative oncology group. N Engl J Med. 1982;306(18):1076–80.CrossRefGoogle Scholar
  4. 4.
    Zon RT. Reforming the community research program: from community clinical oncology program to the National Cancer Institute Community Oncology Research Program. ASCO Educ Book. 2014;2014:e116–9.Google Scholar
  5. 5.
    Coltman CA Jr. Organizations and structures that facilitate community research. Semin Oncol. 1994;21(4 Suppl 7):107–11.PubMedGoogle Scholar
  6. 6.
    Fisher B, Bauer M, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665–73.CrossRefGoogle Scholar
  7. 7.
    Fisher B, Montague E, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer. 1977;39(6):2827–39.CrossRefGoogle Scholar
  8. 8.
    Krag DN, Anderson SJ, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.CrossRefGoogle Scholar
  9. 9.
    Siegel RD, et al. National collaborative to improve oncology practice: the National Cancer Institute Community Cancer Centers Program quality oncology practice initiative experience. J Oncol Pract. 2009;5(6):276–81.CrossRefGoogle Scholar
  10. 10.
    McCaskill-Stevens W. The NCI Community Oncology Research Program: what every clinician needs to know. ASCO Educ Book. 2013;2013:e84–9.Google Scholar
  11. 11.
    Institute of Medicine. Participation by community physicians. In: Institute of Medicine, editor. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press; 2010. p. 197–9.Google Scholar
  12. 12.
    Institute of Medicine. Tapping community practices. In: Institute of Medicine, editor. Implementing a national cancer clinical trials system for the 21st century: second workshop summary. Washington, DC: The National Academies Press; 2013. p. 55–9.Google Scholar
  13. 13.
    NP Office. NCI Community Oncology Research Program (NCORP) Gets, NCI news note, 1. Bethesda, MD: NCI; 2014.Google Scholar
  14. 14.
    Cancer Trials Support Unit: a service of the National Cancer Institute. https://www.ctsu.org/Public/Default.aspx. Accessed 15 Mar 2019.
  15. 15.
    Jacobs SR, et al. Organizational and physician factors associated with patient enrollment in cancer clinical trials. Clin Trials. 2014;11(5):565–75.CrossRefGoogle Scholar
  16. 16.
    Jacobs SR. Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program. Contemp Clin Trials. 2013;34(2):320–5.CrossRefGoogle Scholar
  17. 17.
  18. 18.
    Simmonr RM. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (Alliance) Z1072. Ann Surg Oncol. 2016;23(8):2438–45.CrossRefGoogle Scholar
  19. 19.
    Wolff BG. Alvimopan, a novel, peripherally acting μ opioid antagonist results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004;240(4):728–35.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (TRANSCEND). 2018. https://clinicaltrials.gov/ct2/show/NCT03241459. Accessed 20 Mar 2019.
  21. 21.
    Blake-Michaels M. Applied clinical trials. 2010. http://www.appliedclinicaltrialsonline.com/considerations-medical-device-trials. Accessed 13 Mar 2019.
  22. 22.
    Morton DL. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.CrossRefGoogle Scholar
  23. 23.
    Faries MB. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.CrossRefGoogle Scholar
  24. 24.
    Buchwald H. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323(14):946–55.CrossRefGoogle Scholar
  25. 25.
    Buchwald H. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg. 2010;251(6):1034–40.CrossRefGoogle Scholar
  26. 26.
    Blencowe NS. Standardizing and monitoring the delivery of surgical interventions in randomized clinical trials. Br J Surg. 2016;103(10):1377–84.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of SurgeryLankenau Medical CenterWynnewoodUSA

Personalised recommendations